JP2003533490A - 抗腫瘍剤としてのアロマターゼ阻害剤および抗−ｈｅｒ２モノクローナル抗体 - Google Patents

抗腫瘍剤としてのアロマターゼ阻害剤および抗−ｈｅｒ２モノクローナル抗体

Info

Publication number
JP2003533490A
JP2003533490A JP2001583801A JP2001583801A JP2003533490A JP 2003533490 A JP2003533490 A JP 2003533490A JP 2001583801 A JP2001583801 A JP 2001583801A JP 2001583801 A JP2001583801 A JP 2001583801A JP 2003533490 A JP2003533490 A JP 2003533490A
Authority
JP
Japan
Prior art keywords
her2
aromatase inhibitor
antibody
exemestane
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001583801A
Other languages
English (en)
Japanese (ja)
Inventor
マツシミーニ，ジヨルジヨ
ピシテツリ，ガブリエツラ
プランダレ，デイネシユ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of JP2003533490A publication Critical patent/JP2003533490A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2001583801A 2000-05-15 2001-04-19 抗腫瘍剤としてのアロマターゼ阻害剤および抗−ｈｅｒ２モノクローナル抗体 Withdrawn JP2003533490A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57135500A 2000-05-15 2000-05-15
US09/571,355 2000-05-15
PCT/EP2001/004468 WO2001087334A1 (fr) 2000-05-15 2001-04-19 Inhibiteurs des aromatases et anticorps monoclonaux anti-her2 utiles en tant qu'agents antitumoraux

Publications (1)

Publication Number Publication Date
JP2003533490A true JP2003533490A (ja) 2003-11-11

Family

ID=24283360

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001583801A Withdrawn JP2003533490A (ja) 2000-05-15 2001-04-19 抗腫瘍剤としてのアロマターゼ阻害剤および抗−ｈｅｒ２モノクローナル抗体

Country Status (20)

Country Link
EP (1) EP1282440A1 (fr)
JP (1) JP2003533490A (fr)
KR (1) KR20030014223A (fr)
CN (1) CN1429118A (fr)
AU (1) AU784617B2 (fr)
BR (1) BR0110732A (fr)
CA (1) CA2409652A1 (fr)
CZ (1) CZ20023748A3 (fr)
EA (1) EA005931B1 (fr)
EE (1) EE200200622A (fr)
HK (1) HK1054200A1 (fr)
HU (1) HUP0301877A2 (fr)
IL (1) IL152389A0 (fr)
MX (1) MXPA02011194A (fr)
NO (1) NO20025302D0 (fr)
NZ (1) NZ523004A (fr)
PL (1) PL360153A1 (fr)
SK (1) SK16022002A3 (fr)
WO (1) WO2001087334A1 (fr)
ZA (1) ZA200209815B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
PL217410B1 (pl) 2000-05-19 2014-07-31 Genentech Inc Zastosowanie antagonisty ErbB, antagonista ErbB do zastosowania w metodzie leczenia raka i sposób identyfikacji pacjenta skłonnego do korzystnej odpowiedzi na antagonistę ErbB przy leczeniu raka
EP1377298B1 (fr) * 2001-01-26 2006-08-30 Pfizer Italia S.r.l. Exemestane pour traiter les troubles hormonodependants
GB2375958B (en) 2001-04-09 2005-03-02 George Margetts The use of steroids to lower the levels of cortisol
US7919098B2 (en) 2002-03-26 2011-04-05 Zensun ( Shanghai ) Sci & Tech Co., Ltd. ErbB-3 based methods and compositions for treating neoplasms
KR20050059001A (ko) * 2002-07-01 2005-06-17 사비언트 파마슈티컬즈 인코퍼레이티드 치료적 처리를 위한 조성물 및 방법
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
KR20080019733A (ko) * 2004-07-16 2008-03-04 화이자 프로덕츠 인코포레이티드 항-아이지에프-1알 항체를 사용하는 비-혈액학적악성종양에 대한 조합 치료
CN102580084B (zh) 2005-01-21 2016-11-23 健泰科生物技术公司 Her抗体的固定剂量给药
SI1850874T1 (sl) 2005-02-23 2014-01-31 Genentech, Inc. Podaljšanje časa za napredovanje bolezni ali za preživetje pri pacientkah z rakom na jajčnikih ob uporabi pertuzumaba
WO2007045027A1 (fr) 2005-10-19 2007-04-26 Chavah Pty Ltd Réduction des effets secondaires des inhibiteurs de l'aromatase employés dans le traitement du cancer du sein
AU2008223069B2 (en) 2007-03-02 2012-12-13 F. Hoffmann-La Roche Ag Predicting response to a HER dimerisation inhibitor based on low HER3 expression
EP2171090B1 (fr) 2007-06-08 2013-04-03 Genentech, Inc. Marqueurs d'expression de gène de résistance tumorale à un traitement par inhibiteur her2
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
MY152068A (en) 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
WO2010136569A1 (fr) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulateurs de la signalisation her2 chez des patients exprimant her2 souffrant d'un cancer de l'estomac
CN102892779B (zh) 2010-02-18 2016-12-21 基因泰克公司 神经调节蛋白拮抗剂及其在治疗癌症中的用途
WO2011146568A1 (fr) 2010-05-19 2011-11-24 Genentech, Inc. Prédiction de réponses à un inhibiteur de her
EP2643353A1 (fr) 2010-11-24 2013-10-02 Novartis AG Molécules multi-spécifiques
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
CN102068429B (zh) * 2010-12-28 2011-12-14 西南大学 法倔唑在诱导罗非鱼已分化卵巢转变为功能型精巢中的应用及其诱导方法
CN103890007A (zh) 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 神经调节蛋白抗体及其用途
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
SG11201402510TA (en) 2011-11-30 2014-06-27 Genentech Inc Erbb3 mutations in cancer
WO2013083810A1 (fr) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification de non-répondeurs aux inhibiteurs de her2
JP2015514710A (ja) 2012-03-27 2015-05-21 ジェネンテック， インコーポレイテッド Ｈｅｒ３阻害剤に関する診断及び治療
WO2014015137A2 (fr) * 2012-07-18 2014-01-23 Angion Biomedica Corp. Compositions et méthodes de traitement de maladies dysprolifératives
MX363188B (es) 2012-11-30 2019-03-13 Hoffmann La Roche Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1.
CN107405353B (zh) 2014-10-22 2021-07-30 哈瓦赫治疗有限公司 降低乳房摄影乳腺密度和/或乳腺癌风险的方法
WO2017066827A1 (fr) 2015-10-22 2017-04-27 Havah Therapeutics Pty Ltd Procédés de réduction de la densité mammaire à la mammographie et/ou du risque de cancer du sein
EP3454863A1 (fr) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Polythérapies pour le traitement du cancer
CN107417791B (zh) * 2017-08-17 2020-09-22 合肥瀚科迈博生物技术有限公司 抗人ErbB2双特异性抗体、其制备方法及用途
AU2020287392A1 (en) 2019-06-03 2021-12-23 Havah Therapeutics Pty Ltd Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor and methods for use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.

Also Published As

Publication number Publication date
EE200200622A (et) 2004-06-15
IL152389A0 (en) 2003-05-29
SK16022002A3 (sk) 2003-04-01
AU5630901A (en) 2001-11-26
CZ20023748A3 (cs) 2003-04-16
NZ523004A (en) 2004-09-24
CN1429118A (zh) 2003-07-09
HK1054200A1 (zh) 2003-11-21
AU784617B2 (en) 2006-05-18
BR0110732A (pt) 2003-02-04
PL360153A1 (en) 2004-09-06
NO20025302L (no) 2002-11-05
EP1282440A1 (fr) 2003-02-12
EA005931B1 (ru) 2005-08-25
ZA200209815B (en) 2003-12-03
EA200201213A1 (ru) 2003-04-24
HUP0301877A2 (hu) 2003-09-29
WO2001087334A1 (fr) 2001-11-22
NO20025302D0 (no) 2002-11-05
KR20030014223A (ko) 2003-02-15
MXPA02011194A (es) 2003-03-10
CA2409652A1 (fr) 2001-11-22

Similar Documents

Publication Publication Date Title
JP2003533490A (ja) 抗腫瘍剤としてのアロマターゼ阻害剤および抗−ｈｅｒ２モノクローナル抗体
US20050032759A1 (en) Antitumor combined therapy
AU2001239913B2 (en) Method of treating cancer with anti-neurotrophin agents
US20140134170A1 (en) Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
JP2003512298A (ja) 癌治療のためのｒｈｕＭＡｂＨＥＲ２と組み合わせたドセタキセル
JP2003504413A (ja) 抗腫瘍物質を含む組み合わせ調製物
TW201536319A (zh) 抗腫瘤劑及抗腫瘤效果增強劑
CN113018429A (zh) 治疗卵巢癌的药物组合
AU2024202832A1 (en) Treatment of breast cancer using combination therapies comprising GDC-9545 and a CDK4/6 inhibitor
JP2003505432A (ja) 抗ｅｐ−ｃａｍ抗体と化学療法剤との組合せ
JP2003527437A (ja) 角化細胞増殖因子および上皮増殖因子阻害剤による組み合わせ処置
US20080008704A1 (en) Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
CN112741896A (zh) 一种具缓解抗癌药物抗药性及增加抗癌药物敏感性的医药组合物及其用途
CN115190800A (zh) 一种brd4抑制剂的用途
WO2020176772A1 (fr) Administration d'inhibiteur d'enzyme d'activation sumo et inhibiteurs de points de contrôle
Tokuda et al. Compassionate use of humanized anti-HER2/neu protein, trastuzumab for metastatic breast cancer in Japan
US20230088704A1 (en) A pharmaceutical combination for the treatment of a cancer
EP3449939B1 (fr) Composition pharmaceutique pour inhiber une métastase de cancer, comprenant, en tant qu'ingrédient actif, un anticorps qui se lie spécifiquement au récepteur du facteur de croissance épidermique
Nozawa et al. Triple HER2-blockade with lapatinib, trastuzumab, and pertuzumab for treatment of HER2 positive metastatic breast cancer with lymphangitic carcinomatosis: A case study
CA3210479A1 (fr) Traitement du cancer du sein a l'aide de polytherapies comprenant du gdc-9545 et de l'abemaciclib ou du ribociclib
JP2020125350A (ja) 上皮成長因子受容体に特異的に結合する抗体を有効成分として含む、癌の転移を抑制するための医薬組成物
NZ750260A (en) Antitumor agent and antitumor effect enhancer
NZ614427B2 (en) Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20071012

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20071012

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080416

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090106